Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Burkholderia Infections Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Burkholderia Infections Overview | 9 | 1 |
| Pipeline Products for Burkholderia Infections Comparative Analysis | 10 | 1 |
| Burkholderia Infections Therapeutics under Development by Companies | 11 | 1 |
| Burkholderia Infections Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Burkholderia Infections Pipeline Products Glance | 13 | 3 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Burkholderia Infections Products under Development by Companies | 16 | 1 |
| Burkholderia Infections Products under Investigation by Universities/Institutes | 17 | 1 |
| Burkholderia Infections Companies Involved in Therapeutics Development | 18 | 11 |
| Arno Therapeutics, Inc. | 18 | 1 |
| Bavarian Nordic A/S | 19 | 1 |
| Emergent BioSolutions Inc. | 20 | 1 |
| Eumedica SA | 21 | 1 |
| Grifols, S.A. | 22 | 1 |
| NanoBio Corporation | 23 | 1 |
| Sarepta Therapeutics, Inc. | 24 | 1 |
| Soligenix, Inc. | 25 | 1 |
| Syntiron LLC | 26 | 1 |
| TGV-Laboratories | 27 | 1 |
| Vault Pharma Inc. | 28 | 1 |
| Burkholderia Infections Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 30 |
| Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections Drug Profile | 38 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections Drug Profile | 39 | 1 |
| AR-13 Drug Profile | 40 | 1 |
| ARD-3100 Drug Profile | 41 | 4 |
| ARD-3150 Drug Profile | 45 | 5 |
| Burkholderia pseudomallei vaccine Drug Profile | 50 | 1 |
| Burkholderia vaccine Drug Profile | 51 | 1 |
| Burkholderia vaccine Drug Profile | 52 | 1 |
| dusquetide Drug Profile | 53 | 4 |
| EV-035 Drug Profile | 57 | 2 |
| GC-072 Drug Profile | 59 | 1 |
| melioidosis vaccine Drug Profile | 60 | 1 |
| Mul-1867 Drug Profile | 61 | 1 |
| NB-401 Drug Profile | 62 | 1 |
| SGX-101 Drug Profile | 63 | 1 |
| SGX-943 Drug Profile | 64 | 1 |
| Small Molecules to Inhibit InhA for Infectious Diseases Drug Profile | 65 | 1 |
| temocillin Drug Profile | 66 | 1 |
| VPI-231 Drug Profile | 67 | 1 |
| Burkholderia Infections Dormant Projects | 68 | 1 |
| Burkholderia Infections Discontinued Products | 69 | 1 |
| Burkholderia Infections Product Development Milestones | 70 | 5 |
| Featured News &Press Releases | 70 | 1 |
| May 31, 2016: FDA Grants Soligenix Fast Track Designation for SGX943 for the Treatment of Melioidosis | 70 | 1 |
| Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC | 70 | 1 |
| Aug 14, 2014: US DTRA to fund preclinical work on Evolva s antibiotic GC-072 | 71 | 1 |
| Feb 21, 2014: Bavarian Nordic s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development | 71 | 1 |
| Feb 21, 2014: Bavarian Nordic s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development | 71 | 1 |
| Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis | 72 | 1 |
| Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC | 72 | 1 |
| Oct 15, 2009: NanoBio s Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |